Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Phase 1 Study of KN026 in HER2 Expressing Breast Cancer, Gastric/Gastroesophageal Junction Cancer and other Locally Advanced/Metastatic Solid Tumors

    Cancer Categories
    • Breast,Gastrointestinal (GI),Other
    Karmanos Trial ID
    • 2019-070
    NCT ID
    • NCT03847168
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    Primary
    • To evaluate the safety and tolerability of KN026 To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of KN026
    Secondary
    • To characterize the pharmacokinetics (PK) of KN026
    • To assess the immunogenicity of KN026
    • tO ASSESS THE PRELIMINARY ANTI-TUMOR ACTIVITY OF KN026
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266